Defiance Daily Target 2X Long LLY ETF

Indie Asset Partners LLC increased holdings in Eli Lilly

Eli Lilly Foundation Sells Shares of Eli Lilly

Eli Lilly Annual Meeting Fails to Pass Governance Change Proposals

Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion

Hims &amp; Hers Health Launches Multiple FDA-Approved GLP-1 Drugs

Herbst Group LLC Purchases 1,925 Shares of Eli Lilly in Q4

Eli Lilly Requests UK to Increase Drug Prices in Exchange for Investment

Eli Lilly Announces Plan to Invest $3 Billion Over Decade to Expand Supply Chain in China

WHO Foundation and Eli Lilly Collaborate to Strengthen Obesity Care Systems

Eli Lilly's Clinical Trial Shows Significant Improvement in Psoriasis and Weight Loss with Zepbound and Taltz Combination

Eli Lilly and LiLai Pharmaceutical Co-develop Tolerability Therapy

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

ELIL

LLYX

Donald Trump disclosed stock purchases of up to $680,000 in Eli Lilly as Medicare initiatives advanced GLP-1 drug coverage. The investments coincided with policies benefiting the drugmaker's obesity treatments. Trump's purchases also included shares in West Pharmaceutical Services, valued between $250,000 and $500,000. A spokesperson stated that his investments are managed independently by third-party institutions. Eli Lilly shares rose 2.73% to $1015.09, gaining 9.4% over the past month.

benzinga_article

Eli Lilly

West Pharmaceutical

Direxion Daily LLY Bull 2X Shares

iShares US Pharma

Health Care Select Sector SPDR

VG Health

Thomson Reuters

S&P 500

On May 19, 2026, the S&P 500 closed lower due to rising inflation expectations and higher long-term yields. The healthcare sector outperformed, led by stocks like Becton Dickinson and Eli Lilly, as they are less affected by rising yields. Conversely, the materials sector struggled with declining gold and silver prices, impacted by a stronger dollar, with stocks like Newmont Mining and DuPont seeing losses.

Tip Ranks

Newmont

Becton Dickinson and

Direxion Daily Gold Miners Bull 2X

Wisdomtree Efficient Gold Plus Gold Miners Stgy Fd - ETF

iShares US Medical Devices

iShares MSCI Global Gold Miners

Tradr 2X Long NEM Daily ETF

SPDR S&P Biotech

VanEck Junior Gold Miners ETF

VanEck Gold Miners ETF

Us Gbl GLD & Met

iShares Global Healthcare

Sprott GLD Miners Etf

SPDR S&P Health Equip

Baxter

DexCom

Bio-Techne

DuPont de Nemours

Martin Marietta Materials

Albemarle

CRH Plc

DUPONT DE NEMOURS INC

Top Stock Gainers Today, 5/19/26

President Trump purchased $680,000 in Eli Lilly (LLY) stock around the FDA's approval of a new weight-loss pill. The timing of these trades coincides with favorable government decisions benefiting Lilly, including a Medicare reimbursement pilot program for GLP-1 drugs. Trump's stock trades, disclosed in ethics forms, include various investments across sectors, but Lilly's trades stand out due to their potential impact on the company's revenue growth, projected to exceed $80 billion in 2026.

iShares Biotechnology ETF

Microsoft

NVIDIA

Boeing

Target

Chipotle Mexican Grill

Citigroup

Toronto Dominion Bank

NVIDIA Corporation

Boeing Company

CITIGROUP INC 6.250 NON CUM SER II PFD WI

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

IBBQ

ELIS

LABU

The U.S. Supreme Court denied Eli Lilly's petition, finalizing a $220M judgment for defrauding the Medicaid Drug Rebate Program. This marks a significant victory for whistleblower Ronald J. Streck and his legal team after a 12-year legal battle. The case, initiated in 2014, revealed that Eli Lilly failed to pay required Medicaid rebates following price increases. This decision upholds a unanimous jury verdict and highlights the success of False Claims Act litigation.

prnewswire

Invesco Nasdaq Biotechnology ETF

Direxion Daily LLY Bear 1X Shares

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

07:27 ETWMHW Secures Victory; U.S. Supreme Court Denies Eli Lilly's Petition for Certiorari, Finalizing $220M+ False Claims Act Judgment

The company is riding an incredible tailwind.

Eli Lilly stock: Next stop $2,000?

Eli Lilly has partnered with Caitlin Clark’s foundation to open three multisport community courts in Indianapolis, including two at public schools and one in a park. This initiative is part of Lilly's 150th anniversary celebrations, with the courts designed for basketball, soccer, and futsal. The project involves Musco Lighting and aims to enhance community access to sports facilities. Lilly's campaign, '150 Years of Everything Else,' promotes its brand through various media.

Fiercepharma

Lilly allies with Caitlin Clark for Indianapolis sports courts

LLYZ

The U.S. Supreme Court has rejected Eli Lilly's appeal regarding a $194 million whistleblower judgment for underpaying Medicaid rebates by misreporting drug pricing. The decision upholds the federal False Claims Act, allowing private individuals to sue on behalf of the government. Eli Lilly's stock fell 1.64% to $988.42 following the ruling, with the company arguing that the whistleblower's claims were unfounded and that its pricing practices were industry-standard.

Fidelity

Defiance Daily Target 2X Short LLY ETF

Ondas

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case

NVDQ

Today's market shows mixed results across sectors. Tech stocks see volatility with Oracle down 3.60% and Nvidia falling 1.22%, while Google rises 2.28%. The healthcare sector faces pressure, with Eli Lilly down 1.58%. Financials are mixed, with Bank of America up 1.64% but American Express down 0.58%. Investors are advised to diversify portfolios to navigate sector challenges and capitalize on emerging trends.

Investinglive

T-Rex 2X Inverse NVIDIA Daily Target ETF

YieldMax NVDA Option Income Strategy ETF

T-Rex 2X Long NVIDIA Daily Target ETF

Defiance Daily Target 2X Long ORCL ETF

Direxion Daily GOOGL Bull 2X Shares

Roundhill GOOGL WeeklyPay ETF

Oracle

Micron Tech

Alphabet

Alphabet - C

Amazon

CVS Health

Bank of America

Visa

American Express

ORACLE CORP DEPOSITARY SH REP 1/2000TH PFD SER D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Tech stocks rally while healthcare faces pressure: A closer look at today's market

Eli Lilly was among the pharmaceutical companies denied certiorari by the Supreme Court, which rejected multiple appeals related to healthcare and commercial cases. This decision diminishes the chances of immediate Supreme Court intervention in these matters. Following the news, Eli Lilly's shares fell by 2.2% to $985.25.

fidelity

Direxion S&P Biotech Bear 3X

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals

Eli Lilly (LLY) has emerged as a leader in the obesity drug market with its GLP-1 based products, Mounjaro and Zepbound, significantly boosting its stock. However, concerns about policy uncertainties and elevated expectations suggest that the market may have already priced in much of the growth potential. While demand for obesity treatments remains strong, potential risks could lead to volatility, prompting a neutral stance on LLY.

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference | LLY Stock News

StockTitan

AllianceBernstein

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference | LLY Stock News

Novo Nordisk AS

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

Defiance Daily Target 2X Long LLY ETF(LLYX.US)

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

Top Stock Gainers Today, 5/19/26

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

07:27 ETWMHW Secures Victory; U.S. Supreme Court Denies Eli Lilly's Petition for Certiorari, Finalizing $220M+ False Claims Act Judgment

Eli Lilly stock: Next stop $2,000?